Research programme: Canavan disease therapeutics - Turing Pharmaceuticals

Drug Profile

Research programme: Canavan disease therapeutics - Turing Pharmaceuticals

Alternative Names: TUR-007

Latest Information Update: 21 Nov 2015

Price : $50

At a glance

  • Originator Turing Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Canavan disease

Most Recent Events

  • 18 Nov 2015 Turing Pharmaceuticals and University of Toledo enter into a research agreement for development in Canavan disease
  • 01 Jul 2015 Preclinical trials in Canavan disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top